Enveric Biosciences profit margin ENVB
Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.
- Net margin, 12 months
- n/m
- a quarter missing
- Peer median
- 7.6%
Enveric Biosciences' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | n/a |
| FY2024 | n/a | n/a | n/a |
| FY2023 | n/a | n/a | n/a |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
| FY2019 | −6.0% | −15.8% | 20.4% |
| FY2018 | −39.3% | −16.6% | 20.9% |
| FY2017 | −18.7% | −23.2% | 21.1% |
| FY2016 | −7.9% | −14.9% | 18.1% |
| FY2015 | −4.0% | −3.9% | 33.9% |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year |
|---|---|---|---|
| Q2 FY26 | n/a | n/a | |
| Q1 FY26 | n/a | n/a | |
| Q4 FY25 | n/a | n/a | |
| Q3 FY25 | n/a | n/a | |
| Q2 FY25 | n/a | n/a | |
| Q1 FY25 | n/a | n/a | |
| Q4 FY24 | n/a | n/a | |
| Q3 FY24 | n/a | n/a | |
| Q2 FY24 | n/a | n/a | |
| Q1 FY24 | n/a | n/a | |
| Q4 FY23 | n/a | n/a | |
| Q3 FY23 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Enveric Biosciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| ENVBEnveric Biosciences | n/m |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| Peer median | 7.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Enveric Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.